XJPX4565
Market cap575mUSD
Jan 22, Last price
1,001.00JPY
1D
-1.09%
1Q
-15.81%
Jan 2017
-70.23%
Name
Sosei Group Corp
Chart & Performance
P/E
—
P/S
7.05
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.60%
Rev. gr., 5y
27.23%
Revenues
12.77b
-18.00%
Net income
-7.19b
L
CFO
-5.27b
L
Dividend
Mar 27, 201510 JPY/sh
Earnings
Feb 11, 2025
Profile
Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of HTL0022562, a calcitonin gene related peptide antagonist, which is in Phase I clinical study; HTL0016878 for neurological diseases; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; and TMP301 and BHV3100 for neurological disorders, which is in clinical trials. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2018‑03 | 2017‑03 | 2016‑03 | 2015‑03 | |
| Income | ||||||||||
Revenues | 12,766,000 -18.00% | 15,569,000 -12.10% | ||||||||
Cost of revenue | 23,142,000 | 12,757,000 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (10,376,000) | 2,812,000 | ||||||||
NOPBT Margin | 18.06% | |||||||||
Operating Taxes | (3,487,000) | 696,000 | ||||||||
Tax Rate | 24.75% | |||||||||
NOPAT | (6,889,000) | 2,116,000 | ||||||||
Net income | (7,193,000) -1,982.98% | 382,000 -62.44% | ||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 9,983,000 | |||||||||
BB yield | -8.51% | |||||||||
| Debt | ||||||||||
Debt current | 6,773,000 | 176,000 | ||||||||
Long-term debt | 72,017,000 | 31,311,000 | ||||||||
Deferred revenue | 3,882,000 | 4,791,000 | ||||||||
Other long-term liabilities | 631,000 | 118,000 | ||||||||
Net debt | 26,459,000 | (36,807,000) | ||||||||
| Cash flow | ||||||||||
Cash from operating activities | (5,273,000) | 9,952,000 | ||||||||
CAPEX | (851,000) | (303,000) | ||||||||
Cash from investing activities | (63,791,000) | 1,043,000 | ||||||||
Cash from financing activities | 48,329,000 | (4,887,000) | ||||||||
FCF | (17,011,000) | 2,142,000 | ||||||||
| Balance | ||||||||||
Cash | 49,065,000 | 66,557,000 | ||||||||
Long term investments | 3,266,000 | 1,737,000 | ||||||||
Excess cash | 51,692,700 | 67,515,550 | ||||||||
Stockholders' equity | 32,763,000 | 32,424,000 | ||||||||
Invested Capital | 112,533,000 | 59,895,000 | ||||||||
ROIC | 3.66% | |||||||||
ROCE | 2.95% | |||||||||
| EV | ||||||||||
Common stock shares outstanding | 82,517 | 82,590 | ||||||||
Price | 1,421.00 -33.54% | 2,138.00 12.29% | ||||||||
Market cap | 117,255,956 -33.60% | 176,578,363 13.09% | ||||||||
EV | 143,714,956 | 143,783,363 | ||||||||
EBITDA | (7,898,000) | 4,157,000 | ||||||||
EV/EBITDA | 34.59 | |||||||||
Interest | 2,495,000 | 756,000 | ||||||||
Interest/NOPBT | 26.88% | |||||||||